Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance

Vertex Pharmaceuticals IncorporatedTrade
Vanguard Emerging Markets Stock Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Vertex Pharmaceuticals Incorporated vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $60.33. Which is the better fit depends on your goals.

VRTXVWO
Market Cap
$132.79B
Sector
Health
52-Week High
$529.65$61.24
52-Week Low
$376.62$51.20
Enterprise Value
$126.92B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vertex Pharmaceuticals Incorporated

No Aura AI signal available yet.

Vanguard Emerging Markets Stock Index Fund ETF

VWO trades at $60.47, up 0.85% today, with a bullish technical signal from moving averages but overbought RSI levels. The ETF offers low-cost exposure to emerging markets with a 0.06% expense ratio and a 2.4% dividend yield, attracting institutional inflows as seen in recent SEC filings. Recent news highlights strong investor interest in emerging markets ex-China and AI-driven growth in regions like Taiwan and Thailand.

Outlook is positive due to record capital flows into emerging markets and diversification benefits, but risks include China's economic volatility and currency fluctuations. The ETF's low fees and focus on high-growth economies support long-term potential, though short-term technical indicators suggest caution near resistance at $61.

Returns comparison

Trailing returns across standard periods

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX

About Vanguard Emerging Markets Stock Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.

Read more on VWO